These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 32457139)

  • 1. Inflammation-related plasma and CSF biomarkers for multiple sclerosis.
    Huang J; Khademi M; Fugger L; Lindhe Ö; Novakova L; Axelsson M; Malmeström C; Constantinescu C; Lycke J; Piehl F; Olsson T; Kockum I
    Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12952-12960. PubMed ID: 32457139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the Preanalytical Variability of Plasma and Cerebrospinal Fluid Processing and Its Effects on Inflammation-Related Protein Biomarkers.
    Huang J; Khademi M; Lindhe Ö; Jönsson G; Piehl F; Olsson T; Kockum I
    Mol Cell Proteomics; 2021; 20():100157. PubMed ID: 34597789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
    Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
    PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
    Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
    Mult Scler; 2017 Jan; 23(1):62-71. PubMed ID: 27003946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation.
    Bielekova B; Komori M; Xu Q; Reich DS; Wu T
    PLoS One; 2012; 7(11):e48370. PubMed ID: 23226202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Immune Signature of CSF in Multiple Sclerosis with and without Oligoclonal Bands: A Machine Learning Approach to Proximity Extension Assay Analysis.
    Gaetani L; Bellomo G; Di Sabatino E; Sperandei S; Mancini A; Blennow K; Zetterberg H; Parnetti L; Di Filippo M
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Novel Biomarkers for Diagnosing and Predicting the Progression of Multiple Sclerosis Using TMT-Based Quantitative Proteomics.
    Shi Y; Ding Y; Li G; Wang L; Osman RA; Sun J; Qian L; Zheng G; Zhang G
    Front Immunol; 2021; 12():700031. PubMed ID: 34489947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study.
    Olesen MN; Soelberg K; Debrabant B; Nilsson AC; Lillevang ST; Grauslund J; Brandslund I; Madsen JS; Paul F; Smith TJ; Jarius S; Asgari N
    J Neuroinflammation; 2019 Mar; 16(1):59. PubMed ID: 30857557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases.
    Kušnierová P; Zeman D; Hradílek P; Zapletalová O; Stejskal D
    PLoS One; 2020; 15(5):e0233519. PubMed ID: 32437412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical performances of SPAPLUS® turbidimeter for the quantification of albumin and IgG in serum and cerebrospinal fluid.
    Benard C; Chauzeix J; Blancher A; Puissant-Lubrano B
    Clin Biochem; 2016 Jul; 49(10-11):828-31. PubMed ID: 27048976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis.
    Modvig S; Degn M; Roed H; Sørensen TL; Larsson HB; Langkilde AR; Frederiksen JL; Sellebjerg F
    Mult Scler; 2015 Dec; 21(14):1761-70. PubMed ID: 25698172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can CSF biomarkers predict future MS disease activity and severity?
    Magliozzi R; Cross AH
    Mult Scler; 2020 Apr; 26(5):582-590. PubMed ID: 31965889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
    Romme Christensen J; Komori M; von Essen MR; Ratzer R; Börnsen L; Bielekova B; Sellebjerg F
    Mult Scler; 2019 Jun; 25(7):937-946. PubMed ID: 29775134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers.
    Ottervald J; Franzén B; Nilsson K; Andersson LI; Khademi M; Eriksson B; Kjellström S; Marko-Varga G; Végvári A; Harris RA; Laurell T; Miliotis T; Matusevicius D; Salter H; Ferm M; Olsson T
    J Proteomics; 2010 Apr; 73(6):1117-32. PubMed ID: 20093204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD138 as a Specific CSF Biomarker of Multiple Sclerosis.
    Hinsinger G; Du Trieu De Terdonck L; Urbach S; Salvetat N; Rival M; Galoppin M; Ripoll C; Cezar R; Laurent-Chabalier S; Demattei C; Agherbi H; Castelnovo G; Lehmann S; Rigau V; Marin P; Thouvenot E
    Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200230. PubMed ID: 38669615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.
    Piehl F; Kockum I; Khademi M; Blennow K; Lycke J; Zetterberg H; Olsson T
    Mult Scler; 2018 Jul; 24(8):1046-1054. PubMed ID: 28627962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis.
    Hinsinger G; Galéotti N; Nabholz N; Urbach S; Rigau V; Demattei C; Lehmann S; Camu W; Labauge P; Castelnovo G; Brassat D; Loussouarn D; Salou M; Laplaud D; Casez O; Bockaert J; Marin P; Thouvenot E
    Mult Scler; 2015 Sep; 21(10):1251-61. PubMed ID: 25698171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predictive value of CSF multiple assay in multiple sclerosis: A single center experience.
    De Fino C; Lucchini M; Lucchetti D; Nociti V; Losavio FA; Bianco A; Colella F; Ricciardi-Tenore C; Sgambato A; Mirabella M
    Mult Scler Relat Disord; 2019 Oct; 35():176-181. PubMed ID: 31394405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: A multicenter study.
    Presslauer S; Milosavljevic D; Huebl W; Aboulenein-Djamshidian F; Krugluger W; Deisenhammer F; Senel M; Tumani H; Hegen H
    Mult Scler; 2016 Apr; 22(4):502-10. PubMed ID: 26199348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.